AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Gélinas, Roselle ^a   Mailleux, Florence ^a   Dontaine, Justine ^a   Bultot, Laurent ^a   Demeulder, Bénédicte ^a   Ginion, Audrey ^a   Daskalopoulos, Evangelos P ^a   Esfahani, Hrag ^a   Dubois Deruy, Emilie ^a   Lauzier, Benjamin ^b   Gauthier, Chantal ^b   Olson, Aaron K ^c,d   Bouchard, Bertrand ^d   Des Rosiers, Christine ^d,e   Viollet, Benoit ^f,g,h   Sakamoto, Kei ⁱ   Balligand, Jean Luc ^a   Vanoverschelde, Jean Louis ^a,j   Beauloye, Christophe ^a,j   Horman, Sandrine ^a   Bertrand, Luc ^a   more..

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f INSTITUT COCHIN   (France)

^g CNRS   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ NESTLÉ RESEARCH CENTER   (Switzerland)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P70; TRANSCRIPTION FACTOR NFAT; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; 6-DIAZO-5-OXONORLEUCINE; AMPK ALPHA2 SUBUNIT, MOUSE; AZASERINE; AZO COMPOUND; ENZYME ACTIVATOR; GFPT1 PROTEIN, MOUSE; N ACETYLGLUCOSAMINE; NORLEUCINE; PYRONE DERIVATIVE; THIOPHENE DERIVATIVE; TRANSFERASE; TROPONIN T;

BIOCHEMISTRY; CARDIOLOGY; CARDIOVASCULAR SYSTEM; CELL; ENZYME; ENZYME ACTIVITY; INHIBITION; INHIBITOR; PHYSIOLOGICAL RESPONSE; PROTEIN;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; ENZYME ACTIVATION; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; O GLCNACYLATION; PROTEIN PHOSPHORYLATION; RAT; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CARDIOMEGALY; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; HEART VENTRICLE; KNOCKOUT MOUSE; METABOLISM; NEWBORN; PATHOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; WISTAR RAT;

MUS;

ACETYLGLUCOSAMINE; ACYLATION; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANIMALS, NEWBORN; AZASERINE; AZO COMPOUNDS; CARDIOMEGALY; ENZYME ACTIVATION; ENZYME ACTIVATORS; GENE EXPRESSION REGULATION; GLYCOSYLATION; HEART VENTRICLES; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; NITROGENOUS GROUP TRANSFERASES; NORLEUCINE; PHOSPHORYLATION; PRIMARY CELL CULTURE; PYRONES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; THIOPHENES; TROPONIN T;

EID: 85041048743     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-02795-4     Document Type: Article

References (68)

1. Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B. & Ho, K. K. The progression from hypertension to congestive heart failure. JAMA 275, 1557-1562 (1996).
2. Lorell, B. H. & Carabello, B. A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102, 470-479 (2000).
3. Heineke, J. & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600 (2006).
4. van Berlo, J. H., Maillet, M. & Molkentin, J. D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 123, 37-45 (2013).
5. Tham, Y. K., Bernardo, B. C., Ooi, J. Y., Weeks, K. L. & McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89, 1401-1438 (2015).
6. Viollet, B. et al. AMPK: lessons from transgenic and knockout animals. Front. Biosci. 14, 19-44 (2009).
7. Horman, S., Beauloye, C., Vanoverschelde, J. L. & Bertrand, L. AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Curr. Heart Fail. Rep. 9, 164-173 (2012).
8. Krause, U., Bertrand, L. & Hue, L. Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur. J. Biochem. 269, 3751-3759 (2002).
9. Horman, S. et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 12, 1419-1423 (2002).
10. Hardie, D. G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 47, 185-210 (2007).
11. Chan, A. Y. et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 283, 24194-24201 (2008).
12. Chan, A. Y., Soltys, C. L., Young, M. E., Proud, C. G. & Dyck, J. R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 279, 32771-32779 (2004).
13. Li, H. L. et al. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J. Cell. Biochem. 100, 1086-1099 (2007).
14. Fujita, K. et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 28, 863-870 (2008).
15. Fu, Y. N. et al. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol. Sin. 32, 879-887 (2011).
16. Shibata, R. et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10, 1384-1389 (2004).
17. Cha, H. N. et al. Metformin inhibits isoproterenol-induced cardiac hypertrophy in mice. Korean J. Physiol. Pharmacol. 14, 377-384 (2010).
18. Mailleux, F., Gelinas, R., Beauloye, C., Horman, S. & Bertrand, L. OGlcNAcylation, enemy or ally during cardiac hypertrophy development Biochim. Biophys. Acta 1862, 2232-2243 (2016).
19. Bond, M. R. & Hanover, J. A. O-GlcNAc cycling: A link between metabolism and chronic disease. Annu. Rev. Nutr. 33, 205-229 (2013).
20. Dassanayaka, S. et al. Cardiomyocyte Ogt limits ventricular dysfunction in mice following pressure overload without affecting hypertrophy. Basic Res. Cardiol. 112, 23 (2017).
21. Dassanayaka, S. & Jones, S. P. O-GlcNAc and the cardiovascular system. Pharmacol. Ther. 142, 62-71 (2014).
22. Lunde, I. G. et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol. Genom. 44, 162-172 (2012).
23. Facundo, H. T. et al. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 302, H2122-H2130 (2012).
24. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403-416 (2006).
25. Goransson, O. et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 282, 32549-32560 (2007).
26. Timmermans, A. D. et al. A-769662 potentiates the effect of other AMPactivated protein kinase activators on cardiac glucose uptake. Am. J. Physiol. Heart Circ. Physiol. 306, H1619-H1630 (2014).
27. Huang, Q. et al. Effects of ERK1/2/PPARalpha/SCAD signal pathways on cardiomyocyte hypertrophy induced by insulin-like growth factor 1 and phenylephrine. Life Sci. 124, 41-49 (2015).
28. Stuck, B. J., Lenski, M., Bohm, M. & Laufs, U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J. Biol. Chem. 283, 32562-32569 (2008).
29. Zhang, P. et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52, 918-924 (2008).
30. Yue, T. L. et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J. Biol. Chem. 275, 37895-37901 (2000).
31. Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110-118 (2004).
32. Wilkins, B. J. et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol. Cell Biol. 22, 7603-7613 (2002).
33. Moreno, D., Knecht, E., Viollet, B. & Sanz, P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett. 582, 2650-2654 (2008).
34. Benziane, B. et al. AMP-activated protein kinase activator A-769662 is an inhibitor of the Na(+)-K(+)-ATPase. Am. J. Physiol. Cell Physiol. 297, C1554-C1566 (2009).
35. Zibrova, D. et al. GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. Biochem. J. 474, 983-1001 (2017).
36. Ding, F. et al. O-GlcNAcylation involvement in high glucose-induced cardiac hypertrophy via ERK1/2 and cyclin D2. Amino. Acids 45, 339-349 (2013).
37. Szabo-Fresnais, N., Lefebvre, F., Germain, A., Fischmeister, R. & Pomerance, M. A new regulation of IL-6 production in adult cardiomyocytes by betaadrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. Cell Signal. 22, 1143-1152 (2010).
38. Zarrinpashneh, E. et al. AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem. Biophys. Res. Commun. 376, 677-681 (2008).
39. Takefuji, M. et al. G(13)-mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation 126, 1972-1982 (2012).
40. Xie, Z. et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60, 1770-1778 (2011).
41. Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953-966 (2014).
42. Vanhoutte, L. et al. Variability of mouse left ventricular function assessment by 11.7 Tesla MRI. J. Cardiovasc. Transl. Res. 8, 362-371 (2015).
43. Young, M. E. et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul. Syst. Bio 1, 251-262 (2007).
44. Dubois-Deruy, E. et al. Interplay between troponin T phosphorylation and ON-acetylglucosaminylation in ischaemic heart failure. Cardiovasc. Res. 107, 56-65 (2015).
45. Guigas, B. et al. Beyond AICA riboside: in search of new specific AMPactivated protein kinase activators. IUBMB Life. 61, 18-26 (2009).
46. Scott, J. W. et al. Thienopyridone drugs are selective activators of AMPactivated protein kinase beta1-containing complexes. Chem. Biol. 15, 1220-1230 (2008).
47. Ledee, D. et al. c-Myc alters substrate utilization and O-GlcNAc protein posttranslational modifications without altering cardiac function during early aortic constriction. PLoS ONE 10, e0135262 (2015).
48. Cannon, M. V. et al. Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol. Med. 7, 1229-1243 (2015).
49. Glembotski, C. C. Roles for the sarco-/endoplasmic reticulum in cardiac myocyte contraction, protein synthesis, and protein quality control. Physiology 27, 343-350 (2012).
50. Ngoh, G. A., Hamid, T., Prabhu, S. D. & Jones, S. P. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am. J. Physiol. Heart Circ. Physiol. 297, H1711-H1719 (2009).
51. Luo, B. et al. Chronic hexosamine flux stimulates fatty acid oxidation by activating AMP-activated protein kinase in adipocytes. J. Biol. Chem. 282, 7172-7180 (2007).
52. Cheung, W. D. & Hart, G. W. AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J. Biol. Chem. 283, 13009-13020 (2008).
53. Taylor, R. P., Geisler, T. S., Chambers, J. H. & McClain, D. A. Up-regulation of O-GlcNAc transferase with glucose deprivation in HepG2 cells is mediated by decreased hexosamine pathway flux. J. Biol. Chem. 284, 3425-3432 (2009).
54. Bullen, J. W. et al. Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK). J. Biol. Chem. 289, 10592-10606 (2014).
55. Eguchi, S. et al. AMP-activated protein kinase phosphorylates glutamine: fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. Genes Cells 14, 179-189 (2009).
56. Li, Y. et al. Identification of a novel serine phosphorylation site in human glutamine:fructose-6-phosphate amidotransferase isoform 1. Biochemistry 46, 13163-13169 (2007).
57. Zhong, W. et al. Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. Embo J. 25, 3869-3879 (2006).
58. Chou, T. Y., Hart, G. W. & Dang, C. V. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J. Biol. Chem. 270, 18961-18965 (1995).
59. Ramirez-Correa, G. A. et al. O-linked GlcNAc modification of cardiac myofilament proteins: A novel regulator of myocardial contractile function. Circ. Res. 103, 1354-1358 (2008).
60. Marsh, S. A., Powell, P. C., Dell'italia, L. J. & Chatham, J. C. Cardiac OGlcNAcylation blunts autophagic signaling in the diabetic heart. Life Sci. 92, 648-656 (2013).
61. Beauloye, C., Bertrand, L., Horman, S. & Hue, L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 90, 224-233 (2011).
62. Hart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825-858 (2011).
63. Sanchez Canedo, C. et al. Activation of the cardiac mTOR/p70(S6K) pathway by leucine requires PDK1 and correlates with PRAS40 phosphorylation. Am. J. Physiol. Endocrinol. Metab. 298, E761-E769 (2010).
64. Bertrand, L. et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am. J. Physiol. Heart Circ. Physiol. 291, H239-H250 (2006).
65. Rockman, H. A. et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl Acad. Sci. USA 88, 8277-8281 (1991).
66. Hu, P. et al. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am. J. Physiol. Heart Circ. Physiol. 285, H1261-H1269 (2003).
67. Pelat, M. et al. Rosuvastatin decreases caveolin-1 and improves nitric oxidedependent heart rate and blood pressure variability in apolipoprotein E-/-mice in vivo. Circulation 107, 2480-2486 (2003).
68. Noppe, G. et al. Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKalpha1. J. Mol. Cell Cardiol. 74, 32-43 (2014).